## 3 Results  
The highest frequency regarding the oncology diagnostic was colon cancer (34.2% of total cases) followed by pulmonary cancer (24.1%), pancreatic and rectal cancer (13.8%) and esophageal cancer and liposome (6.9%). All patients were diagnosed with stage IV cancer which means advanced or metastatic cancer.  
Oxaliplatin treated cases represented the highest frequency (62.1%), followed by gemcitabine (20.7%) and cisplatin (17.2%) as seen in Table 1.  
A number of 22 out of 29 (75.9%) patients presented adverse effects after chemotherapy of which the most frequent were nausea (34.5%), loss of appetite, alopecia (27.6%), mucositis, xerostomia, vertigo, prickling sensations and fever (13.8%).  
The highest values of GI score of 3 were present more frequently on tooth 16 (15.4%), followed by 21 (7.4%) and 41 (3.7%). Oppositely, the lowest values were registered on 36 where a score of 1 represented 20%, as observed in Figure 1.  
Similar to the GI results, the GBI showed the highest values at 16 (score 5-15.4%), followed by 21 (score 4-7.4%) and 41 (score 4-3.7%) and the lowest values were present at 36 with a score of 0--20%, as presented in Figure 2.  
The CPITN index presented the highest values at 41 (score 3-14.8% and score 2-48.1%) and 44 (score 2-64%) with treatment needs of plaque and calculus removal, oral hygiene instructions and scaling and root planning.  
The highest values of PD were found at 16 with a mean value of 1.611 mm and 36 with a mean value of 1.464 mm, thus the highest values were found in the lateral areas. Table 2 shows higher overall mean values in the maxilla rather than the mandible.  
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline
**Chemotherapy** & **Number of Cases** & **Mean Dose (mg)** & **Frequency of** & **Cancer Types** \\
**Agent** & **(\%)** & **Mean Dose (mg)** & **Administations (Days)** & **Cancer Types** \\ \hline Cisplatin & 5 (17.2) & 48 & 21 & Pulmonary \\ Oxaliplatin & 18 (62.1) & 181.44 & 14 (N = 5 cases) & Esophagus, Colon, Rectum, \\  & & & 21 (N = 8 cases) & Pancreas \\ Gemcitabine & 6 (20.7) & 1699.33 & 7 & Pulmonary, Pancreas, \\  & & & & Liposarcoma \\ \hline \hline \end{tabular}
\end{table}
Table 1: Lot distribution regarding chemotherapy treatment, dosage, frequency and cancer types.  
Figure 1: Sillness and Loe gingival index mean score percentages distributions on Ramfjord teeth (teeth numbers 16, 21, 24, 36, 41 and 44).  
Determining the concentration of chemotherapy in saliva showed a similar curve for all three agents included in this study, following the same pattern. Lowest concentrations were found in T0, cisplatin and gemcitabine being absent in the saliva samples (OXA T0 = 0.0272 \(\mu\)g/mL) and highest concentration values were found in T1 (CIS T1 = 0.0016 \(\mu\)g/mL, OXA T1 = 0.0507 \(\mu\)g/mL and GEM T1 = 0.0106 \(\mu\)g/mL). After two hours after administration, all three chemotherapy drugs showed a decrease in saliva concentration, as observed in Figure 4a-c.  
Figure 3: CAL mean value distribution on Ramfjord teeth.  
Figure 2: Gingival bleeding index mean score percentage distributions on Ramfjord teeth (teeth numbers 16, 21, 24, 36, 41 and 44).  
Using the Wilcoxon test for ranked comparison we compared the overall chemotherapy concentrations in T0, T1, and T2 and obtained statistical significance, as shown in Table 3.  
We then analyzed the correlation between the GI, GBI, CPITN, PD, and CAL and quantity of chemotherapy found in saliva in T0, T1 and T2 and found no statistical significance.